Agilent Technologies and Ambry Genetics have signed an agreement under which Ambry will use Agilent's SureSelect Target Enrichment System for exome sequencing services, the companies said last week.

Ardy Arianpour, vice president of business development at Ambry, said in a statement that the company is using SureSelect to offer whole-exome capture services for "cancer markers, drug response, and Mendelian disease gene discovery."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.

Gene drives might run into biological resistance, the Economist reports.